(UroToday.com) The 2025 AUA annual meeting featured an advanced prostate cancer session and a presentation by Dr. Neal Shore discussing health-related quality of life, pain and safety outcomes in the ...

The deal sees Endocyte acquire an exclusive worldwide licence for ABX’s phase 3-ready prostate cancer candidate 177Lu-PSMA-617. This is a radioligand therapeutic (RLT) that targets the prostate ...

Dr. Hofman highlighted the various clinical trials exploring the combination of 177Lu-PSMA-617 with other agents to overcome resistance mechanisms and improve patient outcomes. Amir Iravani discussed ...

PSMA-delay castration (DC): An open-label, multicenter, randomized phase 3 study of [177Lu]Lu-PSMA-617 versus observation in patients with metachronous PSMA-positive oligometastatic prostate ...

Dr Norman Swan has shared his thoughts on Joe Biden’s cancer diagnosis, suggesting the former US President was being protected by his family or his doctors. In a statement released on Sunday (US ...

Don't miss out on the headlines from World. Followed categories will be added to My News. In a statement released on Sunday (US time), Mr Biden’s office said the 82-year-old was diagnosed with ...

Don't miss out on the headlines from World. Followed categories will be added to My News. In a statement released on Sunday (US time), Mr Biden’s office announced the 82-year-old was diagnosed ...

Novartis already sells one radioligand therapy – Lutathera (177Lu- oxodotreotide ... has a candidate in late-stage testing, called Lu-PSMA-617, which improved survival in PSMA-positive ...

The trial is designed to assess CBP/p300 inhibitor and the company’s first clinical-stage asset in the pipeline, pocenbrodib, both as monotherapy and in conjunction with olaparib, abiraterone acetate ...